When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

3. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...

4. Fluticasone furoate - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate

   The combination drugs fluticasone furoate/umeclidinium bromide/vilanterol, marketed as Trelegy Ellipta, and fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada, New Zealand) and Relvar Ellipta (EU, UK), [33] [34] [35] are approved for use in the United States for long-term maintenance treatment of airflow obstruction in people ...

5. Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

   www.aol.com/news/glaxo-innoviva-file-approval...

   Main Menu. News

6. Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma - AOL

   www.aol.com/news/glaxo-innovivas-trelegy-ellipta...

   With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

7. Analysis-Ozempic on Wall Street's list for 2027 ... - AOL

   www.aol.com/news/analysis-ozempic-wall-streets...

   Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk's blockbuster ...